Peer Review by Golden Retriever

When the Discord's 'resident clinician' graduated from a veterinary program and you're titrating triple-agonists off a labrador's bloodwork.

Filed under Retatrutide ·Survodutide ·Amycretin · #discord-md ·#stack-life ·#glp-1

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Amycretin · Dual GLP-1 / Amylin Receptor Agonist

Novo Nordisk's investigational unimolecular dual GLP-1 and amylin receptor agonist, advanced in both subcutaneous and oral formulations. Phase 1b/2a SC topline (Lancet 2025) showed up to 24.3% mean weight loss at 36 weeks — among the largest weight-loss signals reported for any single peptide, anywhere. Not approved by any regulator; Phase 2 obesity program underway.

RX: Retatrutide · Survodutide · Amycretin
Dosage: 0.5mg/kg (canine)
Half-life: until the vet logs off
Source: manual
Tags: discord-md , stack-life , glp-1
Stamped: 2026-06-14 · Cycle 024
Lot #: LOT-20260614T01:15:46.343Z